Celularity Inc. Comprehensive Income
Celularity Inc. (CELU) reported Comprehensive Income of -$91.71 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-04-30
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$24.36M.
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$23.07M.
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-06-30 was -$24.53M.
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-03-31 was -$19.75M.
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$91.71M.
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$57.90M.
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$196.15M, a 1481.23% decline from fiscal 2022.
- Celularity Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $14.20M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$24.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$47.44M derived: sum of 2 quarters · filed 2026-04-30 | -$71.96M derived: sum of 3 quarters · filed 2026-04-30 | -$91.71M 10-K · filed 2026-04-30 |
| 2025-09-30 | -$23.07M 10-Q · filed 2025-11-14 | -$47.60M derived: sum of 2 quarters · filed 2025-11-14 | -$67.35M 10-Q · filed 2025-11-14 | -$80.64M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | -$24.53M 10-Q · filed 2025-08-29 | -$44.28M 10-Q · filed 2025-08-29 | -$57.57M derived: sum of 3 quarters · filed 2026-04-30 | -$73.67M derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | -$19.75M 10-Q · filed 2025-08-29 | -$33.05M derived: sum of 2 quarters · filed 2026-04-30 | -$49.15M derived: sum of 3 quarters · filed 2026-04-30 | -$55.63M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$13.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$29.40M derived: sum of 2 quarters · filed 2026-04-30 | -$35.88M derived: sum of 3 quarters · filed 2026-04-30 | -$57.90M 10-K · filed 2026-04-30 |
| 2024-09-30 | -$16.10M 10-Q · filed 2025-11-14 | -$22.59M derived: sum of 2 quarters · filed 2025-11-14 | -$44.60M 10-Q · filed 2025-11-14 | -$37.45M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$6.49M 10-Q · filed 2025-08-29 | -$28.50M 10-Q · filed 2025-08-29 | -$21.35M derived: sum of 3 quarters · filed 2025-08-29 | -$115.22M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | -$22.01M 10-Q · filed 2025-08-29 | -$14.86M derived: sum of 2 quarters · filed 2025-08-29 | -$108.74M derived: sum of 3 quarters · filed 2025-08-29 | -$156.96M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$86.72M derived: sum of 2 quarters · filed 2025-05-08 | -$134.94M derived: sum of 3 quarters · filed 2025-05-08 | -$196.15M 10-K · filed 2025-05-08 |
| 2023-09-30 | -$93.88M 10-Q · filed 2024-12-06 | -$142.09M derived: sum of 2 quarters · filed 2024-12-06 | -$203.30M 10-Q · filed 2024-12-06 | -$179.25M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | -$48.22M 10-Q · filed 2024-11-07 | -$109.58M 10-Q · filed 2024-11-07 | -$85.37M derived: sum of 3 quarters · filed 2024-11-07 | -$80.33M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | -$61.36M 10-Q · filed 2024-10-16 | -$37.15M derived: sum of 2 quarters · filed 2024-10-16 | -$32.12M derived: sum of 3 quarters · filed 2024-10-16 | $15.71M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $24.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $29.24M derived: sum of 2 quarters · filed 2024-07-30 | $77.07M derived: sum of 3 quarters · filed 2024-07-30 | $14.20M 10-K · filed 2024-07-30 |
| 2022-09-30 | $5.04M 10-Q · filed 2024-01-03 | $52.86M derived: sum of 2 quarters · filed 2024-01-03 | -$10.01M 10-Q · filed 2024-01-03 | -$14.05M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $47.83M 10-Q · filed 2023-08-14 | -$15.04M 10-Q · filed 2023-08-14 | -$19.08M derived: sum of 3 quarters · filed 2023-08-14 | $30.86M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$62.87M 10-Q · filed 2023-05-22 | -$66.91M derived: sum of 2 quarters · filed 2023-05-22 | -$16.97M derived: sum of 3 quarters · filed 2023-05-22 | |
| 2021-12-31 | -$4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $45.90M derived: sum of 2 quarters · filed 2023-03-31 | -$100.12M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $49.94M 10-Q · filed 2022-11-10 | -$96.08M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |